[1]
|
Kieffer, T.J., McIntosh, C.H. and Pederson, R.A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 136, 3585-3596. doi:10.1210/en.136.8.3585
|
[2]
|
Vilsboll, T., Krarup, T., Sonne, J., Madsbad, S., Volund, A., Juul, A.G. and Holst, J.J. (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 88, 2706-2713. doi:10.1210/jc.2002-021873
|
[3]
|
Lee, S., Yabe, D., Nohtomi, K., Takada, M., Morita, R., Seino, Y. and Hirano, T. (2009) Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocrine Journal, 57, 119-126.
doi:10.1507/endocrj.K09E-269
|
[4]
|
Kozawa, J., Okita, K., Imagawa, A., Iwahashi, H., Holst, J.J., Yamagata, K. and Shimomura, I. (2010) Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochemical and Biophysical Research Communications, 393, 410-413.
doi:10.1016/j.bbrc.2010.01.134
|
[5]
|
Kamoi, K., Ohara, N., Tomoo, I., Shinozaki, Y., Furukawa, K. and Sasaki, H. (2011) Normal response of active GLP-1 like substances level to test meal in non-obese type 2 diabetic Japanese patients with complications and receiving treatments. Journal of Diabetes & Metabolism, 2, 147. doi:10.4172/2155-6156.1000147
|
[6]
|
Examination Committee of Criteria for “Obesity Disease” in Japan, Japan Society for the Study of Obesity (2002) New criteria for “obesity disease” in Japan. Circulation Journal, 66, 987-992
|
[7]
|
Kamoi, K., Shinozaki, Y., Furukawa, F. and Sasaki, H. (2011) Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues. Endocrine Journal, 58, 905-911.
doi:10.1507/endocrj.K11E-125
|
[8]
|
World Health Organization (1999) Definition, diagnosis and classification of diabetes and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, Geneva.
|
[9]
|
Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., Kasuga, M., Hanafusa, T., Haneda, M. and Ueki, K. (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International, 1, 2-20. doi:10.1007/s13340-010-0006-7
|
[10]
|
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
doi:10.1007/BF00280883
|
[11]
|
The Japan Diabetes Society and the Japan Association for Diabetes Education and Care Committee for Standardized Incretin Measurement (2011) Guideline for incretin measurement. http://www.jds.or.jp
|
[12]
|
Yabe, D., Watanabe, K., Sugawara, K., Kuwata, H., Kitamoto, Y., Sugizaki, K., Fujiwara, S., Hishizawa, M., Hyo, T., Kuwabara, K., Yokota, K., Iwasaki, M., Kitatani, N., Kurose, T., Inagaki, N. and Seino, Y. (2011) Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 3, 70-79. doi:10.1111/j.2040-1124.2011.00141x
|
[13]
|
Toft-Nielsen, M.B., Damholt, M.B., Madsbad, S., Hilsted, L.M., Hughes, T.E., Michelsen, B.K. and Holst, J.J. (2001) Determinants of impaired secretion of glucagonlike peptide-1 in type 2 diabetic patients. The Journal of Clinical Endocrinology & Metabolism, 86, 3717-3723.
doi:10.1210/jc.86.8.3717
|
[14]
|
Ryskjaer, J., Deacon, C.F., Carr, R.D., Krarup, T., Madsbad, S., Holst, J. and Vilsboll, T. (2006) Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology, 155, 485-493. doi:10.1530/eje.1.02221
|
[15]
|
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J.J. and Ferrannini, E. (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes, 57, 1340-1348.
doi:10.2337/db07-1315
|
[16]
|
Vollmer, K., Holst, J.J., Baller, B., Ellrichmann, M., Nauck, M.A., Schmidt, W.E. and Meier, J.J. (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes, 57, 678-687. doi:10.2337/db07-1124
|
[17]
|
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A. and Rotella, C.M. (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia, 48, 1168-1172. doi:10.1007/s00125-005-1749-8
|
[18]
|
Fukase, N., Manaka, H., Sugiyama, K., Takahashi, H., Igarashi, M., Daimon, M., Yamatani, K., Tominaga, M. and Sasaki, H. (1995) Response of truncated glucagonlike peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetologica, 32, 165-169. doi:10.1007/BF00838486
|
[19]
|
Larsen, P.J., Wulff, E.M., Gotfredsen, C.F., Brand, C.L., Sturis, J., Vrang, N., Knudsen, L.B. and Lykkegaard, K. (2008) Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Diabetes, Obesity and Metabolism, 10, 301-311. doi:10.1111/j.1463-1326.2008.00865.x
|
[20]
|
Goke, B., Fuder, H., Wieckhorst, G., Theiss, U., Stridde, E., Littke, T., Kleist, P., Arnold, R. and Lucker, P.W. (1995) Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion, 56, 493-501. doi:10.1159/000201282
|
[21]
|
Cuthbertson, J., Patterson, S., O’Harte, F.P. and Bell, P.M. (2011) Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism, 60, 52-56.
doi:10.1016/j.metabol.2010.01.001
|
[22]
|
Kazakos, K.A., Sarafidis, P.A. and Yovos, J.G. (2008) The impact of diabetic autonomic neuropathy on the incretin effect. Medical Science Monitor, 14, 213-220.
|
[23]
|
Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E. and Gallwitz, B. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes, 53, 654-662.
doi:10.2337/diabetes.53.3.654
|